Your Messages Inbox
Your Article Summary
See Latest ArticlesShire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
Shire, 08/25/09
Shire plc, the global specialty biopharmaceutical company, announces that it has entered into a research–based collaboration with Santaris Pharma A/S, a leading player in RNA–based therapeutics, to develop its proprietary Locked Nucleic Acid technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies business. LNA technology has the benefit of a very quick validated target to proof of concept turnaround, thereby increasing the speed and lowering the cost of development.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Covidien Announces Definitive Agreement to Sell U.S. Radiopharmacies
Covidien, 12/18/09
MediciNova and Avigen Stockholders Approve Merger
Avigen, 12/18/09
GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
CCHIT Appoints Officers
HealthDataManagement, 12/18/09
Article Search
Sponsor